Vulvar lichen sclerosus (vLS), if untreated, results in a 5% to 7% increased lifetime incidence of vulvar squamous cell carcinoma (vSCC) and differentiated vulvar intraepithelial neoplasia (dVIN).1,2 This incidence rate can be reduced by suppressive topical corticosteroid treatment3; however, whether topical corticosteroid therapy can also reduce the rate of vSCC recurrence remains unknown. Current data report a 5-year rate of recurrence of 44% to 47% after surgical treatment.4,5 Furthermore, if a patient had 1 recurrence, their chance of another recurrence within 5 years rises to 80%.5 Determining whether topical corticosteroid treatment after surgery can reduce the risk of recurrence is important because up to 25% of women with vLS report not being treated with topical corticosteroid after vSCC excision.6 If shown to have an association with preventing cancer recurrence, topical corticosteroid therapy could be readily implemented.